Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Oct 27, 2024; 16(10): 3211-3223
Published online Oct 27, 2024. doi: 10.4240/wjgs.v16.i10.3211
Postoperative serum tumor markers-based nomogram predicting early recurrence for patients undergoing radical resections of pancreatic ductal adenocarcinoma
Hang He, Cai-Feng Zou, Feng Yang, Yang Di, Chen Jin, De-Liang Fu
Hang He, Cai-Feng Zou, Feng Yang, Yang Di, Chen Jin, De-Liang Fu, Department of Pancreatic Surgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China
Co-first authors: Hang He and Cai-Feng Zou.
Author contributions: He H concepted and designed the study; Jin C and Fu DL provided administrative support; Yang F and Di Y helped acquire follow-up data; He H and Zou CF assembled data and performed analysis; He H wrote the manuscript. All authors read and approved the manuscript. He H and Zou CF contributed equally to the study.
Supported by National Natural Science Foundation of China, No. 82373012.
Institutional review board statement: This study was reviewed and approved by the Clinical Research Ethics Committee of Huashan Hospital (Approval No. 1037).
Informed consent statement: This study retrospectively included data without any intervention for patients or any disclosure of patients’ information. The informed consent document is not applicable.
Conflict-of-interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hang He, MD, Surgeon, Department of Pancreatic Surgery, Huashan Hospital, Shanghai Medical College, Fudan University, No. 12 Middle Wulumuqi Road, Shanghai 200040, China. hhe10@fudan.edu.cn
Received: June 12, 2024
Revised: August 28, 2024
Accepted: September 2, 2024
Published online: October 27, 2024
Processing time: 107 Days and 23.1 Hours
Core Tip

Core Tip: Patients with early recurrence (ER) of pancreatic ductal adenocarcinoma, have significantly poor survivals. Adjuvant therapy (AT) may prevent or delay ER, but the absence of AT happens to nearly 50% of patients. Predictive systems for ER remain unsatisfactory, and postoperative serum tumor markers (STMs) may change this dilemma. This study demonstrates that postoperative STMs are independent risk factors for ER. We developed a nomogram based on postoperative STMs and improved predicting accuracy for ER. With this nomogram, clinicians can identify patients at high risk for ER and administer individualized AT.